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Edited by Veli-Pekka LehtoAbstract Protein S, a cofactor for activated protein C (aPC) to
inactivate coagulation factors, also plays a pivotal role in inﬂam-
mation. Based on our recent ﬁndings that aPC and protein S
modiﬁes tissue plasminogen activator (tPA)-catalyzed activation
of Glu-plasminogen (Glu-plg), we analyzed possible role of pro-
tein S in cell-associated plasminogen activation and invasive po-
tential of inﬂammatory cells. Monocyte-like THP-1 cells, to
which both plasminogen and tPA bind, enhanced tPA-catalyzed
plasminogen activation, which was partially abolished by protein
S but not by aPC. Protein S attenuated both the plasminogen
binding to THP-1 cells and associated their invasive potential
through Matrigel.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein S is a vitamin K-dependent anticoagulant protein
that functions as a cofactor for activated protein C (aPC) to
inactivate factors Va and VIIIa by limited proteolysis [1]. Its
physiological relevance in regulation of the coagulation cascade
is revealed by the development of life-threatening thrombotic
complications in infants homozygous for protein S deﬁciency
[2,3]. In addition, recent ﬁndings suggest that protein S plays
an important role in inﬂammation [4]. This depends mainly
on the fact that, in plasma, a fraction of protein S exists as a
high molecular mass complex with C4b-binding protein
(C4BP), a soluble inhibitor of the classic complement pathway.
As protein S binds to phosphatidyl serine, principally exposed
to the surface of apoptotic cells and activated platelets through
the c-carboxyl glutamic acid (Gla) domain, the C4BP com-
plexed to protein S is also carried on such cell surfaces. This en-
ables C4BP to accumulate on the surface of cells to be
phagocytosed, and to suppress the processes of phagocytosis
[5] or cell damage [6].Abbreviations: aPC, activated protein C; C4BP, C4b-binding protein;
Gla, c-carboxyl glutamic acid; Glu-plg, Glu-plasminogen; HBSS,
Hanks balanced salt solution; tPA, tissue plasminogen activator
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doi:10.1016/j.febslet.2005.09.080Binding of Glu-plasminogen (Glu-plg), the native form of
plasminogen, onto cell surfaces is also involved in inﬂamma-
tory events. Glu-plg, bound to either ﬁbrin or the cell surface
through its lysine-binding site in kringle domains, acquires a
looser conformation allowing it to be activated more readily
by plasminogen activators (PAs) [7]. This enables plasmin, a
broad-range enzyme, to be generated and located precisely at
the site where proteolytic activity is needed. Recently, we re-
ported that tissue plasminogen activator (tPA)-catalyzed
Glu-plg activation in the presence of poly-lysine, which mimics
C-terminal lysine bearing either ﬁbrin or plasminogen-speciﬁc
binding protein on the cell surface, was modiﬁed by aPC [8].
To assess the physiological relevance of this phenomenon,
we analyzed the eﬀect of aPC and protein S on cell-associated
plasminogen activation. It was found that protein S, but not
aPC, suppressed the extent of Glu-plg binding to the cell sur-
face, as well as tPA-catalyzed Glu-plg activation on THP-1
cells.2. Methods
2.1. Reagents
Human protein S was purchased from Enzyme Research Laborato-
ries (South Bend, IN, USA) and monocyte chemotactic protein 1 was
from Sigma (St. Louis, MO, USA). Human recombinant aPC was
kindly provided by the Chemo-Sero-Therapeutic Research Institute
(Kumamoto, Japan). Tranexamic acid and human recombinant single
chain tPA were kindly provided by Daiichi Seiyaku (Tokyo, Japan).
Human Glu-plg was puriﬁed from freshly frozen human plasma by
aﬃnity chromatography on lysine-Sepharose. Glu-plg was labeled with
biotin, using ECL protein biotinylation module (Amersham Life Sci-
ences, Little Chalfont, UK).
2.2. Cells
THP-1 cells were obtained from Riken Cell Bank (Tokyo, Japan)
and cultured in RPMI-1640 (Sigma) supplemented with 2 mM L-gluta-
mine and 10% fetal calf serum (Biological Industries, Beth Haemek,
Israel) in a 5% CO2 and 95% air atmosphere. Cell density was main-
tained at 0.1–0.6 · 106 cells/ml.
2.3. Plasminogen activation assay
Cell-dependent plasminogen activation was monitored by a contin-
uous chromogenic assay using a plasmin-speciﬁc substrate of S-2251.
Cells were washed three times in Hanks balanced salt solution (HBSS)
before assay and resuspended at 2 · 106 cells/ml. When required, the
cells were preincubated with protein S (100 nM) for 30 min. Glu-plg
(0.5 lM) and S-2251 (0.4 mM) were then added to cells and plasmino-
gen activation was initiated by the addition of tPA (1.9 nM). tPA-cat-
alyzed Glu-plg activation was monitored by the increase in the
absorbance at 405 nm.blished by Elsevier B.V. All rights reserved.
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After washing three times in HBSS, cells were resuspended at
2 · 106 cells/ml and were preincubated with diﬀerent concentrations
of protein S (0–300 nM) for 2 h. Biotin-labeled Glu-plg was then added
(25 nM ﬁnal concentration) and incubated for another 90 min. After
washing three times in HBSS, a 100-ll aliquot of plasminogen elution
buﬀer (2 mM tranexamic acid in 50 mM Tris–HCl buﬀer, pH 7.4, con-
taining 100 mM NaCl) was added to the cells and incubated for
20 min. Cells were then pelleted and the supernatant was frozen at
80 C until assayed. The amount of plasminogen eluted into the
supernatant was assayed by an enzyme-linked immuno-sorbent assay
(ELISA).0.2
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Fig. 1. Eﬀect of THP-1-cells on Glu-plg activation by tPA. tPA-
catalyzed Glu-plg activation was analyzed in the presence (closed
square) or absence (open square) of THP-1 cells. Activation was
initiated by the addition of 1.9 nM t-PA, Glu-plg (0.5 lM) and S-2251
(0.4 mM). Data are shown by means ± S.E.M. (n = 3).
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The amount of plasminogen was assayed by an ELISA method,
using anti-plasminogen polyclonal IgG as a catching antibody
(5.3 lg/ml) and its conjugate with biotin as a tagging antibody. The
buﬀer was phosphate-buﬀered saline, containing 0.1% BSA and 0.1%
Tween 80.
2.6. Invasion assay
Invasive potential of THP-1 cells was evaluated using invasion
chambers (BD BioCoat Matrigel invasion chambers; BD Biosciences
Discovery Labware, Bedford, MA, USA), as described previously
[9]. Inserts, coated with Matrigel, were rehydrated for 2 h with
RPMI-1640 containing 2 mM L-glutamine. THP-1 cells, resuspended
in RPMI-1640 (4 · 104/insert) with Glu-plg (106 nM) and protein S
(100 nM) when required, were placed in the upper chambers and
monocyte chemotactic protein-1 was placed in the lower chambers
(50 ng/ml) as a chemoattractant. The chambers were then incubated
for 24 h at 37 C in a 5% CO2/95% air atmosphere. After the cells
on the upper side of the ﬁlter were removed with a cotton swab, the
migrated cells on the lower side of the ﬁlter were ﬁxed with 70% etha-
nol and stained with Giemsa. The number of stained cells was then
counted in at least three randomly selected microscopic ﬁelds at
200· magniﬁcation and averaged.0.4
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Fig. 2. Eﬀect of protein S on THP-1 cell-dependent enhancement of
plasminogen activation by tPA. After preincubation of THP-1 cells
with (open square) or without (closed square) 100 nM protein S for
30 min, plasminogen activation was monitored as in Fig. 1. Data
obtained in the absence of THP-1 cells with (open circle) or without
(closed circle) 100 nM protein S are also shown. Data are shown by
means ± S.E.M. (n = 3).3. Results
3.1. Protein S attenuates Glu-plg activation by tPA
tPA-catalyzed Glu-plg activation was assayed by a continu-
ous chromogenic assay. The presence of the THP-1 cell suspen-
sion (2 · 106 cells/ml) did not interfere with the assay.
Activation was enhanced by THP-1 cells (2 · 106 cells/ml), as
reported previously [10] (Fig. 1). To avoid the possible eﬀect
of inborn PAs produced in THP-1 cells, the increase in absor-
bance at 405 nm, obtained in the absence of supplemented
tPA, was subtracted, though the value was negligible. Protein
S at 100 nM attenuated Glu-plg activation by tPA in the pres-
ence of THP-1 cells (Fig. 2), whereas it did not evoke any sig-
niﬁcant change in their absence. Since protein S is a cofactor
for aPC and, as reported previously [8,11], aPC modiﬁes
tPA-catalyzed plasminogen activation, possible eﬀects of
aPC, both in the presence and absence of protein S, were ana-
lyzed. aPC did not modify tPA-catalyzed Glu-plg activation
further in the presence of both THP-1 cells and protein S.
Thus, the inhibitory eﬀect of protein S on tPA-catalyzed
Glu-plg activation appears to be cell surface-dependent, but
aPC-independent.
3.2. Eﬀect of protein S on plasminogen binding to THP-1 cells
Since the capacity of a cell surface to bind plasminogen is a
factor in controlling the eﬃcacy of cell surface-dependent plas-
minogen activation, a possible eﬀect of protein S on plasmin-
ogen binding to THP-1 cells was analyzed. As shown in
Fig. 3, protein S attenuated the binding of biotin-labeledGlu-plg to THP-1 cells in a dose-dependent manner. The con-
centration of protein S needed to inhibit plasminogen binding
by 50% (ID50) was approximately 200 nM. When THP-1 cells
were incubated with protein S for diﬀerent time periods (1.5–
3.5 h), the inhibition of plasminogen-binding was not signiﬁ-
cantly changed (data not shown).
3.3. Invasive potential of THP-1 cells was suppressed by protein
S
Since the enhancement of invasion potential is a representa-
tive phenomenon induced by plasmin bound on the surface of
inﬂammatory cells [12], the eﬀect of protein S on the potential
of THP-1 cells to invade through the matrix protein was ana-
lyzed. The number of THP-1 cells invading through Matrigel
was markedly suppressed by protein S at 100 nM (Fig. 4).
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Fig. 3. Eﬀect of protein S on binding of biotin-labeled plasminogen on
THP-1 cells. After preincubation of THP-1 cells with diﬀerent
concentrations of protein S (0–300 nM) for 2 h, the lysine binding
site-dependent binding of biotin-labeled Glu-plg was measured. Data
are shown by means ± S.E.M. (n = 3).
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Fig. 4. Eﬀect of protein S on the invasive potential of THP-1 cells
through Matrigel. The numbers of THP-1 cells migrated to the lower
chambers containing monocyte chemotactic protein-1 from the upper
chambers containing Glu-plg (106 nM) either in the presence or
absence of protein S (100 nM) were counted. Data are shown by
means ± S.E.M. (n = 3).
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cell motility, independent of matrix degradation, by cell sur-
face proteolysis, a similar assay was performed using uncoated
inserts. Protein S did not modify cell migration in this case
(data not shown).4. Discussion
In the present study, it was shown that protein S suppressed
plasminogen-binding on the surface of THP-1 cells, as well as
their invasive potential. We propose that this mechanism ex-
plains, at least in part, the anti-inﬂammatory function of pro-
tein S.As has been reported, THP-1 cells potentiated tPA-catalyzed
Glu-plg activation, most probably by providing a speciﬁc bind-
ing protein for both tPA and plasminogen on the cell surface.
Among several plasminogen-binding molecules on the cell sur-
face, proteins possessing carboxy-terminal lysine are princi-
pally responsible for the enhancement of plasminogen
activation in cells [7]. The enhancement is believed to be the
result of either conformational or proteolytic alteration of
Glu-plg, after binding to the cell surface, to a form that is more
susceptible to activation by Pas, as well as a template mecha-
nism to accumulate both plasminogen and tPA on the cell sur-
face [7]. Several diﬀerent molecules are reported as candidates,
including a-enolase [13], the S-100A10-annexin II complex
[14], cytokeratin-8 [15] and TIP49a [16]. The responsible mol-
ecule seems to vary depending on cell type, but the number of
plasminogen-binding sites on the cell surface essentially deter-
mines the ability of the cells to enhance plasminogen activa-
tion.
Protein S suppressed plasminogen activation only in the
presence of THP-1 cells, suggesting that protein S possibly
diminished the binding capacity of either tPA or plasminogen
on the cell surface. This was conﬁrmed by the ﬁnding that pro-
tein S suppressed the lysine binding site-dependent binding of
biotin-labeled Glu-plg on THP-1 cells. Two diﬀerent mecha-
nisms are suggested to modify the plasminogen-binding capac-
ity of the cell surface. One is modiﬁcation by proteases either
to upregulate by exposing newly developed carboxy-terminal
lysine after cleavage of cell-surface protein by trypsin-like pro-
teases, including plasmin, or to downregulate by removal of
the carboxy-terminal lysine by carboxyl peptidase, including
the thrombin activatable ﬁbrinolysis inhibitor (TAFI) [17].
Another is a non-protease-dependent modiﬁcation of exposure
of the plasminogen-binding molecule to the cell surface, which
is often induced by various stimuli to alter the architecture of
the cell membrane and/or cytoskeleton. The mechanism for
protein S in suppressing plasminogen binding to THP-1 cells
is not known, but the facts that protein S does not possess pro-
tease activity and that the downregulation was aPC-indepen-
dent suggest that the mechanism is not protease-dependent.
Since protein S is known to bind to negatively charged phos-
pholipids on the cell surface through its Gla-domain [1], mem-
brane structure might be modiﬁed by its binding to the cell
surface, thus aﬀecting the exposure of plasminogen-binding
protein on the cell surface. Annexin II, a plasminogen-binding
protein, as a complexed form with S-100A10, is a candidate to
be inﬂuenced by protein S to be exposed to the cell surface,
since it also binds to phosphatidyl serine [18].
Cell-associated ﬁbrinolysis plays an important role in a vari-
ety of physiological and pathological events. It facilitates
migration and invasion of leukocytes, cancer cells and bacte-
rial cells, while participating in eﬀective clot dissolution and/
or angiogenesis in the case of vascular endothelial cells. On
the surface of macrophages, plasminogen activation enhances
their migration to sites of injury and inﬂammation [19,20],
the physiological relevance of which has been demonstrated
clearly by annexin II gene knockout animals [12] and by block-
ing antibody against a-enolase [21]. In our experiments, sup-
pression of plasminogen binding to THP-1 cells by protein S
resulted in the attenuation of the potential of THP-1 cells to
invade through Matrigel toward a chemoattractant of mono-
cyte chemotactic protein-1. Hyper-inﬂammatory responses in
either congenital [2,3] or acquired [22] protein S deﬁciency, be-
6026 T. Hryszko et al. / FEBS Letters 579 (2005) 6023–6026sides procoagulant states, may signify the physiological impor-
tance of this phenomenon. Our ﬁndings in the present study
support the idea that lower concentrations of protein S favor
an exacerbated host response by increasing the accumulation
of inﬂammatory cells in tissues.
In summary, protein S attenuated the potential of THP-1
cells to migrate through the extracellular matrix by suppressing
the binding of plasminogen on the cell surface. This newly
identiﬁed property of protein S may be involved in the patho-
genesis of hyper-inﬂammatory host response and increased
accumulation of cells in tissues when plasma levels of free pro-
tein S are decreased.
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